Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Perrigo Company plc (NYSE: PRGO) is a pure-play self-care and consumer health company whose news flow is closely tied to its over-the-counter (OTC) product portfolio, category performance and strategic initiatives. The company regularly issues updates on its Consumer Self-Care Americas and Consumer Self-Care International segments, highlighting trends in categories such as Upper Respiratory, Pain & Sleep Aids, Digestive Health, Nutrition, Vitamins, Minerals and Supplements, Women’s Health, Skin Care, Oral Care and Healthy Lifestyle.
On this page, readers can follow Perrigo’s earnings announcements, where the company discusses net sales, organic growth, segment performance and the impact of divestitures and exited products. These releases often reference store brand market share gains in OTC categories, performance of key brands and progress under its Three-S plan (Stabilize, Streamline, Strengthen). Updates on Project Energize, the global investment and efficiency program designed to support the One Perrigo growth strategy, are also a recurring theme in recent communications.
Perrigo’s news also covers portfolio actions and strategic reviews. The company has disclosed an agreement to sell its Dermacosmetics branded business in certain European markets and has announced strategic reviews of its Oral Care and infant formula businesses. In addition, readers will find announcements related to dividends, participation in investor conferences and brand-level initiatives, such as collaborations involving Opill®, which Perrigo describes as the first daily birth control pill available without a prescription in the United States.
Investors, analysts and consumers can use this news feed to monitor how Perrigo is positioning its OTC and self-care portfolio, how its store brand and branded businesses are performing across regions and categories, and how management is adjusting the company’s structure and investments in response to market conditions.
Perrigo Company plc (NYSE: PRGO) has declared a quarterly dividend of $0.24 per share, scheduled for payment on September 21, 2021. Shareholders of record as of September 3, 2021 will receive this dividend. The company is noted for providing quality, affordable self-care products and is a leader in the U.S. over-the-counter market, offering more than 9,000 SKUs. The announcement highlights Perrigo's commitment to shareholder returns while emphasizing its strong position in the OTC health market.
Perrigo Company plc (NYSE; TASE: PRGO) is set to disclose its second quarter 2021 financial results on August 11, 2021, at 8:00 A.M. (EDT). The results will be followed by a conference call available via webcast on the investor relations section of their website. Perrigo is a leading provider of affordable OTC health and wellness products, holding a significant market position as the largest store brand OTC player in the U.S. and a Top 10 OTC company in Europe.
Perrigo Company plc (NYSE: PRGO) has successfully completed the sale of its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for $1.55 billion. This strategic divestiture marks a significant milestone in Perrigo's transformation into a leading global consumer self-care entity. CEO Murray S. Kessler emphasized the company's commitment to enhancing self-care product offerings, which has positioned Perrigo as the largest store brand OTC player in the U.S. and a top OTC company in Europe. The company aims to leverage its resources for future growth.
Perrigo Company plc (NYSE: PRGO) announced that President and CEO, Murray S. Kessler, along with CFO, Ray Silcock, will participate in several investor meetings. These include the Barclays Consumer Spring Symposium on May 25, the Oppenheimer 21st Annual Consumer Growth and Ecommerce Conference on June 16 at 9:05 AM EDT, and the Evercore ISI Consumer & Retail Summit on June 17 at 2:45 PM EDT. Investors can find webcasts of these presentations on Perrigo's website.
Perrigo Company plc has agreed to sell its over-the-counter (OTC) businesses in Mexico and Brazil to Advent International. This strategic move aims to enhance margins and is part of Perrigo's Project Momentum cost savings initiative. The sale, expected to finalize in the second half of 2021, follows a review indicating insufficient scale in Latin America. In FY2020, these businesses generated $85 million in sales but were considered dilutive to Perrigo's growth targets. The transaction is anticipated to be margin accretive, with no impact on adjusted diluted earnings per share for 2021.
Perrigo Company plc (PRGO) reported Q1 2021 net sales of $1.01 billion, down 6.8% year-over-year due to pandemic-related pantry loading. Cough/cold season impacts led to a 10.9% decline in organic growth. Adjusted diluted EPS decreased 25.4% to $0.50, compared to $0.67 in Q1 2020. The company reaffirmed its fiscal 2021 outlook, targeting 3% organic sales growth and $2.50-$2.70 adjusted EPS. New partnerships and increased retail foot traffic are expected to support a strong second half of the year.
Perrigo Company plc (NYSE; TASE: PRGO) will announce its fiscal first quarter financial results on May 11, 2021. There will be a conference call at 8:00 a.m. (EDT) to discuss these results, accessible via webcast or phone. Perrigo is the largest store brand OTC player in the U.S. and is also a top OTC company in Europe, offering over 9,000 SKUs and 200 branded products. The release emphasizes the company's commitment to affordable self-care products, while also providing a cautionary note about potential risks affecting future performance.
Perrigo Company plc (NYSE: PRGO) announced a quarterly dividend of $0.24 per share, set for payment on June 22, 2021 to shareholders of record by June 4, 2021. As a prominent provider of quality self-care products, Perrigo is a leader in the U.S. store brand OTC market and is among the top five OTC companies in Europe, with over 200 branded products across 28 countries. The announcement reflects the company's ongoing commitment to returning value to its shareholders while maintaining significant market presence.
Perrigo Company plc (NYSE: PRGO) reported fourth quarter and fiscal year 2020 results, marked by a consolidated net loss of $175 million, translating to a loss of $1.29 per diluted share, against a loss of $19 million or $0.14 per diluted share in Q4 2019. Consolidated net sales decreased by 2.5% to $1.3 billion, heavily impacted by a 5% decline in cough/cold sales. For fiscal 2020, net sales increased by 5% to $5.1 billion, driven by strong e-commerce growth and new product sales. The company expects 3% organic net sales growth and adjusted EPS growth of 7% in 2021.
Perrigo Company plc (NYSE: PRGO) announced a definitive agreement to sell its Generic Rx Pharmaceuticals business to Altaris Capital Partners for $1.55 billion, which includes $1.5 billion in cash. This strategic move aims to transform Perrigo into a pure-play global consumer self-care company with projected revenues over $4 billion. After the deal, Perrigo expects to have more than $2 billion in cash to advance its strategy. The transaction is anticipated to close by Q3 2021 and will enhance Perrigo’s financial predictability and flexibility.